An investigation on behalf of investors of Bioverativ Inc (NASDAQ:BIVV) in connection with the proposed takeover was announced and NASDAQ:BIVV stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 01/31/2018 -- An investigation was announced for investors in NASDAQ:BIVV shares, over whether the takeover of Bioverativ Inc. by Sanofi is unfair.
Investors who purchased shares of Bioverativ Inc (NASDAQ:BIVV) should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain directors of Bioverativ Inc breached their fiduciary duties owed to NASDAQ:BIVV investors in connection with the proposed acquisition.
On January 22, 2018, Sanofi and Bioverativ Inc., have entered into an agreement under which Sanofi will acquire all of the outstanding shares of Bioverativ for $105 per share in cash, representing an equity value of approximately $11.6 billion.
However, the investigation concerns whether the offer is unfair to NASDAQ:BIVV stockholders. More specifically, the investigation concerns whether the Bioverativ Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
On January 30, 2018, NASDAQ:BIVV shares closed at $103.10 per share.
Those who are current investors in Bioverativ Inc (NASDAQ:BIVV) shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels